title: Avoiding adverse events with dabigatran by careful selection of eligible patients.
authors.forename: Ross I
authors.initials: RI
authors.lastname: Baker
authors.forename: Paul
authors.initials: P
authors.lastname: Harper
authors.forename: Claire
authors.initials: C
authors.lastname: McLintock
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D000075202:Contraindications; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D018579:Patient Selection; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran